Skip to main content
. Author manuscript; available in PMC: 2019 Jan 9.
Published in final edited form as: Pharm Res. 2018 Jan 9;35(2):31. doi: 10.1007/s11095-017-2278-0

Fig. 6.

Fig. 6

Kaplan-Meier Survival Plot of mice bearing metastatic brain tumors from human triple negative breast cancer. The mice were treated weekly via IV bolus with vehicle (n=23), IRN-50 (n = 16), nal-IRI-10 (n=8) and nal-IRI-50 (n=9) starting 21 days after intracardiac injection of MDA-MB-231Br-Luc cancer cells. The median survival time was 37 days for vehicle, 35 days for IRN-50, 48 and 50 days for nal-IRI-10 and nal-IRI-50 respectively. The median survival for liposomal irinotecan groups (nal-IRI-10 and nal-IRI-50) significantly increased (P< 0.05) when compared to vehicle group. The groups were compared to vehicle by Log-rank statistical analysis.